Programs

  • Program 1 [2021]

    RESEARCHNPF CONTINUED TO LEAD COLLABORATIVE, TRANSFORMATIONAL RESEARCH BY ENSURING THAT FUNDING EXTRAMURAL RESEARCH REMAINED A PRIORITY. NPF ALSO CONDUCTED RESEARCH FOR THE COMMUNITY IMPACTED BY PSORIATIC DISEASE. PSORIATIC DISEASE RESEARCH ACCOUNTED FOR 34% OF TOTAL NPF EXPENSES IN FY21. THIS INCLUDED THE COMPETITIVE RENEWAL OF THE PSA DIAGNOSTIC TEST GRANT WITH FUNDING DEDICATED TO THE DEVELOPMENT OF A DIAGNOSTIC TEST FOR PSORIATIC ARTHRITIS (PSA), NPF SUCCESSFULLY LAUNCHED THE MORE THAN SKIN DEEP MENTAL HEALTH GRANT, WHICH FUNDS RESEARCH AIMED AT ADDRESSING MENTAL HEALTH ISSUES, A MAJOR PSORIATIC DISEASE COMORBIDITY. COMPETITIVE RENEWAL OF THE PSORIASIS PREVENTION INITIATIVE GRANTS OCCURRED. THESE GRANTS SUPPORT PROJECTS FROM MULTI-INSTITUTIONAL, MULTI-DISCIPLINARY TEAMS WITH THE GOAL OF IDENTIFYING AN INTERVENTION THAT WILL PREVENT THE ONSET OF PSORIATIC DISEASE, DISEASE RELAPSE, OR RELEVANT COMORBIDITIES. THE NPF RESEARCH TEAM PUBLISHED SEVERAL ABSTRACTS AND PAPERS AND BROUGHT THE INTERNALLY GENERATED DATA TO THE COMMUNITY. THEY ALSO LED A SUCCESSFUL EFFORT TO PUBLISH AN INFOGRAPHIC TO EDUCATE OTHERS ABOUT PSORIASIS BEING A SYSTEMIC, IMMUNE-MEDIATED DISEASE WITH SEVERAL COMORBIDITIES IMPACTING OVERALL HEALTH OUTCOMES. NPF HOSTED A RESEARCH SESSION IN CONJUNCTION WITH THE SOCIETY OF INVESTIGATIVE DERMATOLOGY. THE CITIZEN PSCIENTIST, AN ON-LINE PATIENT REGISTRY PLATFORM, WAS VALIDATED, AND THE PEER REVIEWED PUBLICATION THAT NPF OVERSEES, THE JOURNAL OF PSORIASIS AND PSORIATIC ARTHRITIS, DOUBLED THE NUMBER OF ORIGINAL RESEARCH SUBMISSIONS. IN PARTNERSHIP WITH OTHER NPF FUNCTIONAL TEAMS, A GRANT WAS SUBMITTED TO THE CENTERS FOR DISEASE CONTROL WITH THE GOAL OF RAISING AWARENESS AND EDUCATING HEALTHCARE WORKERS ABOUT PSORIATIC DISEASE. IN COLLABORATION WITH THOUGHT LEADERS AND STAKEHOLDERS, NPF WAS INSTRUMENTAL IN THE INCLUSION OF PSORIATIC DISEASE IN THE ACCELERATED MEDICINES PARTNERSHIP FOR AUTOIMMUNE AND IMMUNE-MEDIATED DISEASES, A PUBLIC/PRIVATE PARTNERSHIP WHICH WILL BRING MILLIONS OF DOLLARS TO RESEARCH OVER THE NEXT 5 YEARS.
    Geographies
    Not indicated
    Dates
    Jul 1, 2020 – Jun 30, 2021
    Source
    990
    No causes provided
    No populations provided
    –
    $3.7M

  • Program 2 [2021]

    MEDICAL PROFESSIONAL EDUCATIONTHE MAJORITY OF NPF PROGRAMS WERE HELD VIRTUALLY, DUE TO THE ONGOING COVID-19 PANDEMIC. THE NPF MEDICAL AFFAIRS TEAM SUCCESSFULLY DEVELOPED NEW APPROACHES TO ENSURE ENGAGEMENT AND TO BEST MEET THE EDUCATIONAL NEEDS OF PROVIDERS AT EVERY STAGE OF THEIR CAREER. THE NPF COVID-19 TASK FORCE CONTINUED TO OFFER UPDATED DATA-BASED GUIDANCE STATEMENTS FOR NPF, PROVIDERS, AND THE COMMUNITY. THE TASK FORCE IS A MULTIDISCIPLINARY GROUP OF PROVIDERS CHARGED WITH CLOSELY MONITORING THE EMERGING DATA AND PROVIDING GUIDANCE ON THE RISKS OF COVID-19, THE ADVANCEMENTS IN TREATMENTS, AND VACCINATION CONSIDERATIONS FOR THOSE LIVING WITH PSORIATIC DISEASE. NPF CONTINUED TO FOCUS EFFORTS ON COLLABORATION BETWEEN DERMATOLOGISTS AND RHEUMATOLOGISTS, WHICH IS ESSENTIAL TO IMPROVE THE DIAGNOSIS AND TREATMENT OF PSA. NPF ALSO INCORPORATED A FOCUS ON COLLABORATIVE CARE BETWEEN ALL PROVIDERS WITHIN A PRACTICE, PARTICULARLY ADVANCED PROVIDERS AND OTHER SPECIALTIES SUCH AS CARDIOLOGISTS. THE VIRTUAL GRAND ROUNDS PROGRAM WAS VERY POPULAR, AS WAS THE ADVANCE PRACTICE PSORIASIS RECOGNITION PROGRAM, WHICH IS SPECIFICALLY DESIGNED TO ADDRESS KNOWLEDGE AND PRACTICE GAPS AMONG PHYSICIAN ASSISTANTS AND NURSE PRACTITIONERS. THE SUCCESSFUL 23RD ANNUAL NPF RESIDENTS MEETING WAS HELD VIRTUALLY. NPF COMPLETED AN EDUCATIONAL PROGRAM AIMED AT MEDICAL SCHOOLS TO HELP STUDENTS GAIN A DEEPER UNDERSTANDING OF PSORIATIC DISEASE. THIS PROGRAM WILL BE PROVIDED TO MEDICAL SCHOOLS IN FY22 TO ENSURE PSORIASIS IS INCLUDED IN THE VERY LIMITED DERMATOLOGY CURRICULA. NPF HELD AN INAUGURAL PAYER EDUCATION PROGRAM. ACCESS TO THE EFFECTIVE AND SAFE TREATMENTS IS CRITICAL AND HAVING INSURERS UNDERSTAND PSORIATIC DISEASE IS IMPERATIVE TO PROPER FORMULARY DEVELOPMENT AND APPROVALS.
    Geographies
    Not indicated
    Dates
    Jul 1, 2020 – Jun 30, 2021
    Source
    990
    No causes provided
    No populations provided
    –
    $652.2K

  • Program 3 [2021]

    ADVOCACYNPF WORKED TO ENSURE PATIENTS HAVE AFFORDABLE ACCESS TO THE TREATMENTS THEY NEED, INCLUDING LEGISLATION TO ADDRESS HARMFUL COPAY ACCUMULATOR ADJUSTMENT PROGRAMS. NPF SUCCESSFULLY WORKED TO PASS LEGISLATION ADDRESSING THESE PROGRAMS IN SEVERAL STATES. AS OF OCT. 2021, 12 STATES HAVE NOW PROTECTED PATIENTS FROM THESE PROGRAMS. NPF WAS INSTRUMENTAL IN STEP THERAPY REFORM VICTORIES IN OREGON, NEBRASKA, AND ARKANSAS. AS OF OCT. 2021, NPF BEEN A PART OF STEP THERAPY IN 29 STATES. NPF HAS INCREASED SUPPORT FOR FEDERAL STEP THERAPY LEGISLATION TO LEVELS NOT PREVIOUSLY SEEN AND HAS BEEN A LEADING VOICE ON THE PREPONDERANCE OF TELEHEALTH DURING THE COVID PANDEMIC. NPF ALSO LEVERAGED TENS OF THOUSANDS OF ADVOCATES TO WORK FOR HEALTH INSURANCE COVERAGE IMPROVEMENTS FOR THE MILLIONS OF PEOPLE LIVING WITH PSORIATIC DISEASE, WHILE ALSO WORKING TO IMPROVE THE SAFETY AND AFFORDABILITY OF PSORIASIS AND PSA TREATMENTS AND INCREASING FEDERAL FUNDING FOR PSORIATIC DISEASE RESEARCH.
    Geographies
    Not indicated
    Dates
    Jul 1, 2020 – Jun 30, 2021
    Source
    990
    No causes provided
    No populations provided
    –
    $856.7K